Abstract 1512P
Background
Life expectancy has currently increased and pancreaticoduodenectomy (PD) is being performed more frequently on elderly patients in Japan. Surgical treatment for pancreatic ductal adenocarcinoma (PDAC) in patients over 80 years old is increasingly accepted, although it may lead to a decline in quality of life after surgery. Currently, there are no definitive indications for PD in octogenarians. This study aims to examine the surgical indications for PD in this age group, focusing on clinical background and perioperative and postoperative outcomes.
Methods
This retrospective analysis included patients with PDAC who underwent PD between 2012 and 2022. Patients aged ≥80 years were categorized as the Elderly (E) group, while those <80 years were classified as the Non-elderly (N) group. We compared clinical backgrounds, perioperative, and postoperative outcomes between the groups.
Results
PD was performed on 147 patients with PDAC. The median age was 71 years (range 45-85). Twenty-two patients (15.0%) were in the E group and 125 (85.0%) in the N group. The median Charlson comorbidity index (CCI) was significantly higher in the E group (6, range 5-10) compared to the N group (4, range 1-11; p
Conclusions
PD could be safely performed in elderly patients in good physical condition, with the survival benefit of PD for PDAC appearing as promising in elderly patients as in non-elderly patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Keio University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1937P - Clinical characteristics and prognosis of pediatric patients with papillary thyroid carcinoma
Presenter: Junko Akaishi
Session: Poster session 18
1938P - Nomogram for predicting lung metastases in patients with papillary thyroid cancer under 55 years old
Presenter: Huiyun Yang
Session: Poster session 18
1939P - BrafV600E-induced cancer inflammation in a mouse model of thyroid tumorigenesis
Presenter: Sima Kumari
Session: Poster session 18
1940TiP - Sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory thyroid carcinoma and anaplastic thyroid carcinoma: The phase II SETHY, GETNE-T2318 trial design
Presenter: Alejandro Garcia Alvarez
Session: Poster session 18
1941TiP - Neoadjuvant pembrolizumab in high-risk thyroid cancer (NePenTHe)
Presenter: Claudia Leli
Session: Poster session 18
1924P - Efficacy and safety of lenvatinib in patients with chemotherapy-naive advanced or recurrent thymic carcinoma: A multicenter retrospective study
Presenter: Daisuke Hazama
Session: Poster session 18
1923P - Real-world management and outcome of thymic carcinomas in a tertiary German center
Presenter: Antonia Margineanu
Session: Poster session 18
1922P - Targeted resequencing designed specifically for thymic epithelial tumours confirmed the high prevalence of GTF2I mutations
Presenter: Iacopo Petrini
Session: Poster session 18
1921P - Molecular analysis of mesothelioma reveals mutations as prognostic biomarkers for patients treated with the combination of ipilimumab and nivolumab
Presenter: Angelica Rigutto
Session: Poster session 18
1920P - Multiomics analysis of malignant pleural mesothelioma and the effect of immune checkpoint inhibitors
Presenter: Akiko Tateishi
Session: Poster session 18